Key facts
- This page summarizes Rashmi Virendra Ramchandani's Form 4 filing for BIOMARIN PHARMACEUTICAL INC (BMRN).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Jan 2026, 18:12.
Rashmi Virendra Ramchandani - 20 Jan 2026 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)
- Reporting relationship
- VP, Chief Accounting Officer
- Issuer ticker
- BMRN
- Reported as of
- 20 Jan 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Tae Sang Yoo, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Rashmi Virendra Ramchandani filed Form 4 for BIOMARIN PHARMACEUTICAL INC (BMRN) on 22 Jan 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002106034
Primary reporting owner
Ramchandani Rashmi Virendra
- Relationship
- VP, Chief Accounting Officer
- Address
- C/O BIOMARIN PHARMACEUTICAL, 770 LINDARO STREEET, SAN RAFAEL
- Signature
- /s/ Tae Sang Yoo, Attorney-in-Fact
- Signature date
- 22 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BMRN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +18,540
- Change %
- Price
- $0.000000
- Shares after
- 18,540
- Date
- 20 Jan 2026
- Ownership
- Direct
- Footnotes
- F1
BMRN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +7,070
- Change %
- +38%
- Price
- $0.000000
- Shares after
- 25,610
- Date
- 20 Jan 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BMRN
transaction
Derivative
Stock Option (Right to Buy Common Stock)
Award
- Transaction value
- $0
- Shares
- +18,220
- Change %
- Price
- $0.000000
- Shares after
- 18,220
- Date
- 20 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,220
- Exercise price
- $56.31
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Restricted stock units granted on January 20, 2026. Price not applicable.
Footnote F2
Option grant vests 12/48th on January 20, 2027 and 1/48th on the 20th day of each month thereafter.